Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 7, 2022

SHAREHOLDER ALERT: Robbins LLP Investigates Aquestive Therapeutics, Inc. (AQST) on Behalf of Shareholders

Business Wire December 21, 2021

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company's NDA for Libervant(TM) (diazepam) Buccal Film

GlobeNewswire December 20, 2021

Aquestive Therapeutics Added to NASDAQ Biotechnology Index

GlobeNewswire December 17, 2021

Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)

GlobeNewswire December 13, 2021

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

GlobeNewswire November 29, 2021

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 17, 2021

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

GlobeNewswire November 2, 2021

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions

GlobeNewswire October 25, 2021

Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET

GlobeNewswire October 14, 2021

Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement

GlobeNewswire October 6, 2021

IntelGenx and Aquestive Therapeutics Partner with Leading Men's Health Company to Market Tadalafil Oral Films in the U.S.

GlobeNewswire September 29, 2021

Aquestive Therapeutics to Participate in Three Investor Conferences in September

GlobeNewswire September 7, 2021

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant(TM) Related Capital Under Current Debt Agreement

GlobeNewswire August 9, 2021

Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 6, 2021

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance

GlobeNewswire August 3, 2021

Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8:00 a.m. ET

GlobeNewswire July 21, 2021

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant(TM) (diazepam) Buccal Film

GlobeNewswire July 19, 2021

Aquestive Therapeutics Resubmits New Drug Application for Libervant(TM) (diazepam) Buccal Film

GlobeNewswire June 24, 2021

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

GlobeNewswire June 23, 2021